Global Hematologic Malignancies Market

Hematologic Malignancies Market size was valued at US$ 3.37 Bn. in 2021 and the total revenue is expected to grow at 4.3% through 2021 to 2029, reaching nearly US$ 4.73 Bn.

Hematologic Malignancies Market Overview:

Cancers of the blood, bone marrow, and lymph nodes are known as hematologic malignancies. Acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML)), myeloma, and lymphoma (Hodgkin's and non-(NHL)) Hodgkin's are all included in this categorization. Last year, hematologic malignancies accounted for 9% of all newly diagnosed cancers in the United States, with lymphomas (particularly NHLs) being more frequent than leukemias and myeloma.

Hematologic Malignancies Market Snapshot

To know about the Research Methodology :- Request Free Sample Report

Hematologic Malignancies Market Dynamics:

The market is likely to be driven by an increase in the prevalence of blood cancer and a greater focus on the development of innovative treatments. Blood cancers are the fifth most prevalent malignancy worldwide and the second main cause of cancer death. Leukemia, lymphoma, and multiple myeloma are the three most prevalent blood malignancies. Every year, more than 300,000 people are diagnosed with leukemia and 400,000 with lymphoma around the world.

The oncology category is seeing the most acquisitions and cooperation, with huge pharma companies cooperating. In 2021, there were a lot of collaborations in cancer therapies, which shows how popular this field is. Various organizations and research institutes from all around the world are working to discover new hematologic malignancy medicines.

Furthermore, the hematologic malignancies market is predicted to rise due to the development of new regulatory approvals for novel medications for blood cancer. For example, Pfizer announced in 2015 that the FDA has designated inotuzumab (antibody-drug conjugate) as a breakthrough therapy for acute lymphoblastic leukemia.

Hematologic Malignancies Market Segment Analysis:

The Acute lymphocytic leukemia segment is dominating the Type segment of the Hematologic Malignancies Market:

Acute lymphocytic leukemia (ALL) is the most common kind of leukemia, accounting for 56% of occurrences in adolescents and 80% of children in the past few years. As of the presence of best-selling brands like Rituxan, Imbruvica, and Glivec, which are estimated to be among the biggest revenue-generating oncology medications, leukemia was the largest segment in 2017. Due to a solid product pipeline and planned commercialization, acute myeloid is expected to increase at the quickest rate during the forecast period.

The Chemotherapy segment is considered to supplement the growth of the Hematologic Malignancies Market.

Chemotherapy, which is the initial line of treatment, was the most popular part in 2017. Chemotherapy is the standard treatment for most types of blood cancer, and depending on the type of cancer, a specific medicine or combination of drugs is utilized. Due to an increase in cancer incidence, demand for chemotherapy medications is expected to rise. Cancer is the second biggest cause of death worldwide, according to the World Health Organization (WHO), with an estimated 9.6 million deaths in 2018.

Further, Increased frequency of malignancies such as breast Caner, lung cancer, prostate, leukaemia, and lymphoma, as well as an increase in the elderly population and government healthcare spending increase the global market for chemotherapeutic medications. The global market is bolstered by increased expenditure in anti-cancer drug research and development, as well as increased demand for advanced cancer treatments. The worldwide chemotherapy medications market is also expected to benefit from increased awareness about cancer and its treatment, as well as early detection. Hence, this factor is further estimated to lift the growth of the market.

Hematologic Malignancies Market Regional Insights:

North America is estimated to dominate the growth of the Hematologic Malignancies Market.

In 2021, North America dominated the hematologic malignancy market, with a market share of approximately 42.3%. The growth of the region is attributed to the presence of key players, developed healthcare infrastructure, and the availability of branded pharmaceuticals. Furthermore, favorable government efforts and an increase in the number of research collaborations are projected to propel the market forward. The extensive proportion of the analyzed market in North America is due to the presence of key companies, a high prevalence of blood cancer patients, developed healthcare infrastructure, and the availability of branded pharmaceuticals.

Additionally, favorable government efforts and an increase in the number of research partnerships are likely to boost market expansion. For example, in December 2021, the Leukemia and Lymphoma Society (LLS) announced a collaboration to form alliances with leading cancer institutions and foundations to co-fund nearly USD 17 million in research grants to help patients with leukemia, lymphoma, myeloma, and other blood cancers find effective treatment options.

The objective of the report is to present a comprehensive analysis of the Hematologic Malignancies Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the Hematologic Malignancies Market dynamics, structure by analyzing the market segments and project the Hematologic Malignancies Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Hematologic Malignancies Market make the report investor’s guide.

Hematologic Malignancies Market Scope: Inquire before buying

Hematologic Malignancies Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)

Hematologic Malignancies Market, Key Players are

1. Glenmark Pharmaceuticals Inc
2. GlaxoSmithKline
3. Boehringer Ingelheim International GmbH
4. Pfizer, Inc.
5. F. Hoffmann-LA Roche lt
6. Sanofi-Aventis
7. Bristol-Myers Squibb Company
8. AbbVie, Inc.
9. Novartis AG
10. Celgene Corporation
11. Johnson & Johnson Services, Inc
12. Takeda Pharmaceutical Company Limited
13. Sanofi
14. AstraZeneca
15. Amgen Inc.
16. Byer AG

FAQs:

1. What is the Hematologic Malignancies market value in 2022?
Ans: Hematologic Malignancies market value in 2022 was estimated as 3.51 Billion USD.

2. What is the Hematologic Malignancies market growth?
Ans: The Hematologic Malignancies market is anticipated to grow with a CAGR of 4.3% in the forecast period and is likely to reach USD 4.71 Billion by the end of 2029.

3. Which Type segment is expected to dominate the Hematologic Malignancies market during the forecast period?
Ans: Chemotherapy was the largest segment in 2019, as it is the first line of treatment. For most types of blood cancer, chemotherapy is the usual treatment and a particular drug or combination of drugs is used, based on the type of cancer.

4. Who are the key players in the Hematologic Malignancies market?
Ans: Some key players operating in the Hematologic Malignancies market include Pfizer, Inc.; F. Hoffmann-LA Roche ltd; Sanofi-Aventis; Bristol-Myers Squibb Company; AbbVie, Inc.; Novartis AG; GlaxoSmithKline PLC; Celgene Corporation; Johnson & Johnson Services, Inc.; and Takeda Pharmaceutical Company Limited.

5. What is the key driving factor for the growth of the Hematologic Malignancies market?
Ans: Growing incidence of blood cancer and increasing focus on the development of new treatments are expected to drive the market.